| Primary |
| Product Used For Unknown Indication |
22.5% |
| Drug Use For Unknown Indication |
10.4% |
| Prophylaxis |
9.7% |
| Antifungal Prophylaxis |
9.0% |
| Bronchopulmonary Aspergillosis |
7.9% |
| Aspergillosis |
5.0% |
| Onychomycosis |
4.4% |
| Histoplasmosis |
4.4% |
| Fungal Infection |
3.6% |
| Hypertension |
2.9% |
| Diffuse Large B-cell Lymphoma |
2.8% |
| Acute Lymphocytic Leukaemia |
2.7% |
| Bronchopulmonary Aspergillosis Allergic |
2.5% |
| Systemic Mycosis |
2.1% |
| Cystic Fibrosis |
2.0% |
| Nail Tinea |
1.8% |
| Asthma |
1.7% |
| Acute Myeloid Leukaemia |
1.6% |
| Immunosuppression |
1.6% |
| Multiple Myeloma |
1.6% |
|
| Drug Interaction |
19.6% |
| Drug Ineffective |
12.7% |
| Death |
7.6% |
| Bronchopulmonary Aspergillosis |
4.3% |
| Pyrexia |
4.3% |
| Rhabdomyolysis |
4.3% |
| Tremor |
4.3% |
| Ileus Paralytic |
4.0% |
| Pneumonia |
4.0% |
| Rash |
4.0% |
| Neurotoxicity |
3.6% |
| Respiratory Failure |
3.6% |
| Epilepsy |
3.3% |
| Neuropathy Peripheral |
3.3% |
| Cholestasis |
2.9% |
| Drug Resistance |
2.9% |
| Electrocardiogram Qt Prolonged |
2.9% |
| Myalgia |
2.9% |
| Oedema Peripheral |
2.9% |
| Candida Infection |
2.5% |
|
| Secondary |
| Burkitt's Lymphoma |
13.7% |
| Prophylaxis |
12.8% |
| Product Used For Unknown Indication |
12.2% |
| Drug Use For Unknown Indication |
11.3% |
| Antifungal Prophylaxis |
6.4% |
| Bronchopulmonary Aspergillosis |
6.2% |
| Aspergillosis |
4.5% |
| Immunosuppression |
4.2% |
| Bronchopulmonary Aspergillosis Allergic |
3.3% |
| Phaehyphomycosis |
3.1% |
| Fungal Infection |
2.8% |
| Onychomycosis |
2.6% |
| Acute Myeloid Leukaemia |
2.4% |
| Asthma |
2.3% |
| Pneumonia |
2.3% |
| Diffuse Large B-cell Lymphoma |
2.0% |
| Keratitis Fungal |
2.0% |
| Systemic Mycosis |
2.0% |
| Hypertension |
2.0% |
| Atypical Mycobacterial Infection |
1.9% |
|
| Renal Impairment |
11.7% |
| Drug Interaction |
9.6% |
| Tremor |
6.5% |
| Death |
6.2% |
| Ubiquinone Decreased |
5.8% |
| Drug Ineffective |
5.2% |
| Rhabdomyolysis |
5.2% |
| Hepatic Function Abnormal |
4.8% |
| Pyrexia |
4.8% |
| Renal Failure |
4.8% |
| Interstitial Lung Disease |
4.5% |
| White Blood Cell Count Decreased |
4.5% |
| Ileus Paralytic |
3.8% |
| Bronchopulmonary Aspergillosis |
3.4% |
| Drug Resistance |
3.4% |
| Oedema Peripheral |
3.4% |
| Haemolytic Anaemia |
3.1% |
| Neutrophil Pelger-huet Anomaly Present |
3.1% |
| Pericarditis |
3.1% |
| Systemic Mycosis |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.1% |
| Prophylaxis |
17.7% |
| Infection Prophylaxis |
7.2% |
| Aplastic Anaemia |
6.3% |
| Drug Use For Unknown Indication |
5.8% |
| Acute Myeloid Leukaemia |
4.5% |
| Antifungal Prophylaxis |
4.5% |
| Prophylaxis Against Graft Versus Host Disease |
4.3% |
| Multiple Myeloma |
3.7% |
| Premedication |
3.6% |
| Bone Marrow Conditioning Regimen |
3.6% |
| Hiv Infection |
3.4% |
| Antiviral Prophylaxis |
2.0% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.6% |
| Hypertension |
1.5% |
| Constipation |
1.5% |
| Antibiotic Prophylaxis |
1.3% |
| Acute Lymphocytic Leukaemia |
1.2% |
| Myelodysplastic Syndrome |
1.1% |
| Fungal Infection |
1.1% |
|
| White Blood Cell Count Decreased |
15.2% |
| Pyrexia |
8.7% |
| Sepsis |
8.3% |
| Pneumonia |
7.4% |
| Thrombocytopenia |
7.3% |
| Uveitis |
5.0% |
| Platelet Count Decreased |
4.7% |
| Febrile Neutropenia |
4.6% |
| Vomiting |
4.6% |
| Drug Ineffective |
4.2% |
| Renal Failure Acute |
3.6% |
| Venoocclusive Liver Disease |
3.6% |
| Respiratory Failure |
3.3% |
| Renal Failure |
3.0% |
| Stomatitis |
3.0% |
| Acute Graft Versus Host Disease |
2.9% |
| Pancytopenia |
2.9% |
| Interstitial Lung Disease |
2.7% |
| Renal Impairment |
2.6% |
| Graft Versus Host Disease |
2.5% |
|
| Interacting |
| Product Used For Unknown Indication |
17.9% |
| Acute Lymphocytic Leukaemia |
9.0% |
| Drug Use For Unknown Indication |
6.3% |
| Fungal Infection |
6.3% |
| Atrial Fibrillation |
6.0% |
| Immunosuppressant Drug Therapy |
5.6% |
| Atypical Mycobacterial Infection |
5.0% |
| Bronchopulmonary Aspergillosis |
5.0% |
| Mycobacterium Avium Complex Infection |
4.3% |
| Antifungal Prophylaxis |
4.0% |
| Heart Rate Abnormal |
4.0% |
| Heart Rate Increased |
4.0% |
| Prophylaxis |
4.0% |
| Bronchial Secretion Retention |
3.0% |
| Fungaemia |
3.0% |
| Systemic Candida |
3.0% |
| Scedosporium Infection |
2.7% |
| Asthma |
2.3% |
| Hypertension |
2.3% |
| Obsessive-compulsive Disorder |
2.3% |
|
| Drug Interaction |
35.5% |
| Idiopathic Pneumonia Syndrome |
6.6% |
| Hypotension |
5.3% |
| Ileus Paralytic |
5.3% |
| Cardiac Arrest |
3.9% |
| Staphylococcal Sepsis |
3.9% |
| Tuberculosis |
3.9% |
| Ubiquinone Decreased |
3.9% |
| Blood Creatine Phosphokinase Increased |
2.6% |
| Drug Toxicity |
2.6% |
| Histoplasmosis |
2.6% |
| Hyperglycaemia |
2.6% |
| Hypertension |
2.6% |
| Multiple Myeloma |
2.6% |
| Myopathy |
2.6% |
| Neuropathy Peripheral |
2.6% |
| Oedema Peripheral |
2.6% |
| Progressive Multifocal Leukoencephalopathy |
2.6% |
| Pulmonary Alveolar Haemorrhage |
2.6% |
| Swelling |
2.6% |
|
